TP53 mutations in AML confer resistance to CAR T-cell therapy through exhaustion of CAR T-cells, and dysregulation of the mevalonate and Wnt pathways in AML and CAR T-cells, respectively. Targeting ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...